Gene Replacement Therapy for GJB2-Related Hearing Loss

Time: 1:15 pm
day: Post Conference Day

Details:

• Review of GJB2 gene mutations, the most common cause of congenital hearing loss
• Development of OTO-825 for GJB2 gene therapy
• Preclinical proof-of-concept: OTO-825 rescues cochlear morphology and hearing function

Speakers: